BTK, a key target in MM drug therapy, has a positive regulatory effect on stem genes (OCT4, SOX2, NANOG, and MYC) through the Akt/Wnt/β-Catenin pathway and enhances the self-renewal ability of MM cells. Here, AKT1 is linked to Miyoshi myopathy.